CCR 20th Anniversary Commentary: Setting the Stage for Nanoparticle Albumin-Bound Paclitaxel-How Far Science Has Come.

Abstract

In this phase I pharmacokinetic study of ABI-007, which was published in the May 1, 2002, issue of Clinical Cancer Research, Ibrahim and colleagues provided the framework needed for subsequent studies to confirm the benefits of ABI-007 over solvent-based formulations. Since the study's publication, experiments have highlighted the importance of drug-delivery systems, the immune system in cancer biology, and immunoregulatory properties of taxane compounds.

• Authors: Sami I Bashour, Nuhad K Ibrahim
• Journal: Clinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 21 Issue 9 Pg. 1975-7 (May 01 2015) ISSN: 1557-3265 [Electronic] United States
• PMID: 25934886 (Publication Type: Journal Article, Review)
• Copyright: ©2015 American Association for Cancer Research.

Chemical References

• Albumin-Bound Paclitaxel
• Antineoplastic Agents

Topics

• Albumin-Bound Paclitaxel (pharmacology)
• Anniversaries and Special Events
• Antineoplastic Agents (administration & dosage, pharmacokinetics)
• Drug Delivery Systems
• Humans
• Nanoparticles (therapeutic use)
• Neoplasms (drug therapy)